Portal de Periódicos da CAPES

NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice

2000; Elsevier BV; Volume: 408; Issue: 1 Linguagem: Inglês

10.1016/s0014-2999(00)00709-3

1879-0712

Giovambattista De Sarro, Antonio Siniscalchi, Guido Ferreri, Luca Gallelli, Angela De Sarro,

Biochemical Analysis and Sensing Techniques

The anticonvulsant activity of riluzole against sound-induced seizures was studied in the DBA/2 mouse model. Riluzole (0.1–4 mg kg−1, intraperitoneal (i.p.)) produced dose-dependent effects with ED50 values for the suppression of tonic, clonic and wild running phases of 0.72, 1.38 and 2.71 mg kg−1, respectively. Riluzole also protected DBA/2 mice from seizures induced by an intracerebroventricular (i.c.v.) injection of N-methyl-d-aspartate (NMDA) with ED50 values of 3.03 and 5.0 mg kg−1 for tonus and clonus, respectively. Pretreatment with glycine, an agonist to the glycine/NMDA receptors, shifted the dose–response effect of riluzole to the right (ED50=6.53 against tonus and 9.34 mg kg−1 vs. clonus). Similarly, d-serine, an agonist at the glycine site, shifted the ED50 of riluzole against the tonic component of audiogenic seizures from 0.72 to 1.97, and that against clonus from 1.38 to 2.77 mg kg−1. Riluzole was also potent to prevent seizures induced by administration of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), an AMPA/kainate receptor agonist (ED50=1.80 and 3.35 mg kg−1, against tonus and clonus, respectively). Pretreatment with aniracetam, a positive allosteric modulator of AMPA/kainate receptors, shifted the dose–response curve of riluzole to the right (ED50=1.78 against tonus and 2.58 mg kg−1 vs. clonus). The data indicate that riluzole is an effective anticonvulsant drug in the genetic model of seizure-prone DBA/2 mice. Our findings suggest that the anticonvulsant properties of riluzole depend upon its interaction with neurotransmission mediated by both the glycine/NMDA and the AMPA/kainate receptor complex.